3billion, possessing technological capabilities in gene therapy, surged in tandem with broader sector strength fueled by growth in the gene therapy market.

Investor sentiment across the sector improved as peers such as LabGenomics and GC Genome rallied amid the expansion of the global gene therapy market. In terms of investor flows, retail buying drove share price gains, while foreign and institutional investors were net sellers. Although no specific company disclosures or contract details were confirmed, broader industry momentum appears to have been reflected in the stock price.